Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesOtorhinolaryngology (ENT)SummaCare Implantable Sinus Stents Coverage | Open…
    Ask Trek AI about this page
    CurrentSummaCarePolicy N/A

    Implantable Sinus Stents Policy

    Customize your policy alerts

    Sign up for all summacare policy alerts

    Know when summacare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage of implantable sinus stents, including drug-eluting implants such as Propel and Sinuva, for SummaCare Commercial and Medicare members.

    Policy Summary
    PayerSummaCare
    PolicyImplantable Sinus Stents Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 8, 2026
    Last ReviewOct 8, 2026
    Next Review DateN/A
    Key ActionClaims for implantable sinus stents, including Propel and Sinuva, may be denied because the devices are considered experimental, investigational, and unproven.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Noncovered procedure and product codes listed
    2Lines of business addressed
    18+Minimum age for noncovered nasal-polyp indication
    E&ICoverage status for implantable sinus stents

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Implantable sinus stents: experimental and investigational

    Implantable sinus stents are not covered for Commercial or Medicare members and are considered experimental, investigational, and unproven for all lines of business.

    Noncoverage: Implantable sinus stents, including devices with or without drug-eluting capability, are not covered. Available research has not shown that they improve health outcomes compared with standard care, such as packing and saline irrigation, and their effectiveness has not been established.

    Applies to use following sinus surgery, recurrent polyposis, maintenance of postoperative sinus ostial patency following endoscopic sinus surgery, and treatment of nasal polyps following ethmoid sinus surgery.

    Propel/Sinuva after ethmoid sinus surgery

    The following specific indication is not covered.

    Noncovered nasal-polyp indication: Use of a Propel or Sinuva sinus implant to treat nasal polyps after ethmoid sinus surgery in a patient 18 years of age or older is not covered.Age 18 years or older

    This indication is specifically identified as not covered.

    Drug-eluting devices used to maintain postoperative sinus ostial patency following endoscopic sinus surgery are considered experimental and investigational because their effectiveness has not been established.

    Drug-eluting devices used to treat nasal polyps following ethmoid sinus surgery are considered experimental and investigational because their effectiveness has not been established.

    Noncovered Codes

    CPT Codes not coveredCPTNot Covered
    31299Unlisted procedure , accessory sinuses [when specified as insertion of a drug eluting sinus stent]
    HCPCS Codes not coveredHCPCSNot Covered
    J7402Mometasone furoate sinus implant, (Sinuva), 10 micrograms
    S1091Stent, non-coronary, temporary, with delivery system (Propel)

    Provider and Claims Guidance

    Denial Risk

    Experimental and Investigational Device

    Claims for implantable sinus stents, with or without drug-eluting capability, may be denied as experimental, investigational, and unproven for commercial and Medicare members. Evidence has not established improved outcomes compared with standard care, and no research-based clinical guidelines recommend postoperative sinus stents; CMS has no NCD or LCD for implantable sinus stents.

    • Applies to use for recurrent polyposis, following sinus surgery, maintaining postoperative sinus ostial patency after endoscopic sinus surgery, or treating nasal polyps following ethmoid sinus surgery.
    • A drug-eluting device used for these indications is also considered experimental and investigational because effectiveness has not been established.
    Denial Risk

    Nasal-Polyp Indication Not Covered

    Do not represent Propel or Sinuva sinus implants as covered for treatment of nasal polyps after ethmoid sinus surgery in patients 18 years of age or older. This indication is not covered and claims may be denied.

    Background

    Implantable sinus stents are surgically inserted scaffolds intended to expand within the sinus, support internal nasal structures, and help prevent scar formation after sinus surgery. Drug-eluting or drug-releasing devices may continuously release corticosteroids, antibiotics, or saline and may be biodegradable. Available research has not established improved health outcomes compared with standard care, such as packing and saline irrigation, and research-based clinical guidelines do not recommend postoperative sinus stents.

    Definitions

    Drug-eluting stent (DES) or implant
    DefinitionA surgically inserted scaffold that releases a loaded drug or saline locally and continuously in a controlled manner for a desired period.
    MaterialSome drug-eluting stents or implants are made of biodegradable material and are absorbed by the body.
    Common nasal-stent drugsCommonly used drugs include corticosteroids such as dexamethasone, fluticasone, and mometasone, as well as antibiotics.
    Implantable sinus stent
    DefinitionA postoperative sinus implant intended to prop open the sinus, support the bony structure inside the nose, and prevent scar formation.
    ExamplesPropel Sinus Implant and Sinuva sinus implant.
    PlacementThe device is implanted during sinus surgery, where it expands to support the sinus and internal nasal structures.
    Policy Summary
    PayerSummaCare
    PolicyImplantable Sinus Stents Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 8, 2026
    Last ReviewOct 8, 2026
    Next Review DateN/A
    Key ActionClaims for implantable sinus stents, including Propel and Sinuva, may be denied because the devices are considered experimental, investigational, and unproven.
    SourceLink
    On This Page
    Coverage CriteriaNoncovered CodesProvider and Claims GuidanceBackgroundDefinitions